Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAS combined with esketamine for early postoperative anxiety and depression after wound repair
ChiCTR2400085836Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine in burn injury, Peptic ulcer disease (PUD) and wound (4 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Postoperative anxiety and depression. Started Jun 2024; status: recruiting.
02
Drugs
esketamine
03
Conditions
burn injuryPeptic ulcer disease (PUD)wound
Beyond the preview
Go deeper on ChiCTR2400085836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085836.